News

January 31, 2019
|
Category:

Dewpoint Therapeutic’s $60M Series A funding receives significant attention

The announcement of the launch of Dewpoint Therapeutics, with $60 Million Series A funding has received significant attention from media and analysts. Read a selection of the key coverage via the links below.

Read more on bioworld.com

Read more on european-biotechnology.com

Read more on fiercebiotech.com

Read more on xconomy.com

Read more on wsj.com

Media Contact

media@dewpointx.com

Investor Contact

Michael Fenn, PH.D.
Head of External Innovation
Dewpoint Therapeutics
mfenn@dewpointx.com
Dewpoint Therapeutics
451 D Street, Suite 104
Boston, MA 02210
USA
© 2019-2024 - Dewpoint Therapeutics

Design: SALIENCE Communication / Publiepress
Scientific animation: Visual Science